학술논문
Role of antibodies, inflammatory markers, and echocardiographic findings in post-acute cardiopulmonary symptoms after SARS-CoV-2 infection
Document Type
article
Author
Durstenfeld, Matthew S; Peluso, Michael J; Kelly, J Daniel; Win, Sithu; Swaminathan, Shreya; Li, Danny; Arechiga, Victor M; Zepeda, Victor Antonio; Sun, Kaiwen; Shao, Shirley J; Hill, Christopher; Arreguin, Mireya I; Lu, Scott; Hoh, Rebecca; Tai, Viva W; Chenna, Ahmed; Yee, Brandon C; Winslow, John W; Petropoulos, Christos J; Kornak, John; Henrich, Timothy J; Martin, Jeffrey N; Deeks, Steven G; Hsue, Priscilla Y
Source
JCI Insight. 7(10)
Subject
Language
Abstract
Shortness of breath, chest pain, and palpitations occur as postacute sequelae of COVID-19, but whether symptoms are associated with echocardiographic abnormalities, cardiac biomarkers, or markers of systemic inflammation remains unknown. In a cross-sectional analysis, we assessed symptoms, performed echocardiograms, and measured biomarkers among adults more than 8 weeks after confirmed SARS-CoV-2 infection. We modeled associations between symptoms and baseline characteristics, echocardiographic findings, and biomarkers using logistic regression. We enrolled 102 participants at a median of 7.2 months following COVID-19 onset; 47 individuals reported dyspnea, chest pain, or palpitations. Median age was 52 years, and 41% of participants were women. Female sex, hospitalization, IgG antibody against SARS-CoV-2 receptor binding domain, and C-reactive protein were associated with symptoms. Regarding echocardiographic findings, 4 of 47 participants (9%) with symptoms had pericardial effusions compared with 0 of 55 participants without symptoms; those with effusions had a median of 4 symptoms compared with a median of 1 symptom in those without effusions. There was no strong evidence for a relationship between symptoms and echocardiographic functional parameters or other biomarkers. Among adults more than 8 weeks after SARS-CoV-2 infection, SARS-CoV-2 RBD antibodies, markers of inflammation, and, possibly, pericardial effusions are associated with cardiopulmonary symptoms. Investigation into inflammation as a mechanism underlying postacute sequelae of COVID-19 is warranted.